Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Monsanto rejects Bayer's sweetened offer, open to talks

Published 07/19/2016, 12:50 PM
© Reuters. A Monsanto logo is pictured in the company headquarters in Morges
DOW
-
BAYGN
-
SYENF
-
DD
-
MS
-
MON
-
HDJA
-

By Greg Roumeliotis and Ludwig Burger

(Reuters) - U.S. seed company Monsanto Co (N:MON) turned down a sweetened $64 billion acquisition offer from Bayer AG (DE:BAYGn), but said it was open to further talks with the German healthcare and chemicals group as well as other parties.

The widely expected rejection puts pressure on Bayer to sweetens its offer, at least enough to get access to Monsanto's books. The two companies have been in discussions about a potential confidentiality agreement, Reuters reported on Monday.

Monsanto said on Tuesday its board unanimously viewed Bayer's latest bid as "financially inadequate and insufficient to ensure deal certainty."

"Monsanto remains open to continued and constructive conversations with Bayer and other parties to assess whether a transaction that the board believes is in the best interest of Monsanto share owners can be realized," the company said.

Bayer will examine Monsanto's response to the revised offer, a company spokesman said.

The German company disclosed last Thursday that it increased its bid by $3 per share. Its latest $125-per-share offer is the largest all-cash bid on record. Bayer also offered a $1.5 billion reverse antitrust breakup fee, equivalent to about 2.3 percent of the deal's value.

By comparison, the breakup fee ChemChina offered in order to acquire Swiss peer Syngenta (S:SYNN) should the deal not go through is $3 billion, representing 7 percent of the $43 billion transaction value.

Monsanto would like Bayer to sweeten its offer further, including increasing the breakup fee, before providing Bayer access to financial information, according to people familiar with the matter who asked not to be identified discussing private discussions.

Monsanto's shares were up 0.3 percent while Bayer shares were down 1.2 percent at 91.87 euros.

Access to confidential information has been a major sticking point in Bayer's negotiations with Monsanto ever since the German company offered to acquire Monsanto in May.

Bayer argued last week that it had comprehensively addressed Monsanto's questions about financing and regulatory matters and said it was prepared to make certain commitments to regulators, if required, to complete a deal.

Henderson Global Investors (L:HGGH), an investor in Bayer, has called for a vote on the proposed takeover of Monsanto, which it said threatened the long-term strength of the German company. Some other Bayer investors have also expressed concerns the company may overpay to secure a deal.

The seeds and agrochemicals industry has been jolted by several large deals in the past year as low crop prices and belt-tightening by farmers pressured earnings.

Syngenta AG, which Monsanto tried to buy last year, agreed in February to be acquired by ChemChina for $43 billion. Dow Chemical Co (N:DOW) and DuPont (N:DD) struck a $130 billion mega-merger late last year.

Morgan Stanley & Co (NYSE:MS) and Ducera Partners are Monsanto's financial advisers and Wachtell, Lipton, Rosen & Katz is its legal adviser.

© Reuters. A Monsanto logo is pictured in the company headquarters in Morges

As of Monday's close, Monsanto shares had risen 5.3 percent since Bayer disclosed its higher offer on July 14. Bayer shares have fallen about 1 percent in the same period.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.